Inhibition of the IL-6 signaling pathway: A strategy to combat chronic inflammatory diseases and cancer

被引：126

作者：

Ataie-Kachoie, Parvin ^{[1
]}

Pourgholami, Mohammad H. ^{[1
]}

Morris, David L. ^{[1
]}

机构：

[1] Univ New S Wales, Dept Surg, St George Hosp SESIAHS, Sydney, NSW 2217, Australia

来源：

CYTOKINE & GROWTH FACTOR REVIEWS | 2013年 / 24卷 / 02期

基金：

英国医学研究理事会;

关键词：

Interleukine-6; Cancer; Inflammatory diseases; Siltuximab; Tocilizumab; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ANTI-INTERLEUKIN-6; MONOCLONAL-ANTIBODY; NF-KAPPA-B; JUVENILE IDIOPATHIC ARTHRITIS; SILTUXIMAB CNTO 328; RHEUMATOID-ARTHRITIS; RECEPTOR ANTIBODY; PROSTATE-CANCER; TRANSCRIPTION FACTOR; PRECLINICAL MODELS;

D O I：

10.1016/j.cytogfr.2012.09.001

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

070307 [化学生物学]; 071010 [生物化学与分子生物学];

摘要：

Interleukin (IL)-6 is a pro-inflammatory cytokine that produces multifunctional effects. Deregulated IL-6 production and signaling are associated with chronic inflammatory diseases, auto-immunity and cancer. On this basis, inhibition of IL-6 production, its receptors or the signaling pathways are strategies currently being widely pursued to develop novel therapies for a wide range of diseases. This survey aims to provide an updated account of why IL-6 inhibitors are shaping up to become an important class of drugs potentially useful in the treatment of ailments and in particular in inflammation and cancer. In addition we discuss the role of different agents in modulating IL-6 and also recent clinical studies targeting IL-6 in inflammation-mediated diseases and cancer. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：163 / 173

页数：11

共 149 条

[1]

Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis [J].

Abnet, C. C. ;

Freedman, N. D. ;

Kamangar, F. ;

Leitzmann, M. F. ;

Hollenbeck, A. R. ;

Schatzkin, A. .

BRITISH JOURNAL OF CANCER, 2009, 100 (03) :551-557

[2]

Adachi Y, 2010, ANTICANCER RES, V30, P1947

[3]

Salford Faculty Dean visits Hong Kong health unit [J].

British Dental Journal, 2009, 207 (12) :569-569

[4]

Ara T, 2010, EUROPEAN J CANC

[5]

The growth-inhibitory effects of dexamethasone on renal cell carcinoma In Vivo and In Vitro [J].

Arai, Yasuyuki ;

Nonomura, Norio ;

Nakai, Yasutomo ;

Nishimura, Kazuo ;

Oka, Daizo ;

Shiba, Masahiro ;

Nakayama, Masashi ;

Takayama, Hitoshi ;

Mizutani, Yoichi ;

Miki, Tsuneharu ;

Okuyama, Akihiko .

CANCER INVESTIGATION, 2008, 26 (01) :35-40

[6]

The effects of IL-6 on cell adhesion and E-cadherin expression in breast cancer [J].

Asgeirsson, KS ;

Olafsdottir, K ;

Jonasson, JG ;

Ogmundsdottir, HM .

CYTOKINE, 1998, 10 (09) :720-728

[7]

Mechanisms of disease - Nuclear factor-kappa b - A pivotal transcription factor in chronic inflammatory diseases [J].

Barnes, PJ ;

Larin, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (15) :1066-1071

[8]

PROTECTIVE ROLE OF INTERLEUKIN-6 IN THE LIPOPOLYSACCHARIDE-GALACTOSAMINE SEPTIC SHOCK MODEL [J].

BARTON, BE ;

JACKSON, JV .

INFECTION AND IMMUNITY, 1993, 61 (04) :1496-1499

[9]

A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer [J].

Bayliss, Trevor J. ;

Smith, Jeff T. ;

Schuster, Michael ;

Dragnev, Konstantin H. ;

Rigas, James R. .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (12) :1663-1668

[10]

ALLEVIATION OF SYSTEMIC MANIFESTATIONS OF CASTLEMANS DISEASE BY MONOCLONAL ANTI-INTERLEUKIN-6 ANTIBODY [J].

BECK, JT ;

HSU, SM ;

WIJDENES, J ;

BATAILLE, R ;

KLEIN, B ;

VESOLE, D ;

HAYDEN, K ;

JAGANNATH, S ;

BARLOGIE, B .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (09) :602-605

← 1 2 3 4 5 6 7 8 9 10 →